论文信息 - A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy - 字舞流文

A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy

M. Dyer | M. Terol | K. Sułek | J. Radford | F. Awan | G. Verhoef | M. Di Nicola | M. Trněný | A. Guidetti | A. Gianni | A. Barbui | L. Siraudin | C. Patti | Andrés López | M. Canales | C. Oprea | A. Janíková | D. Ben Yehuda | L. Hatteville | Paul G. Montgomery | Sandrine Schwab